Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update
Vivani Medical reported Q2 2026 financial results, including a net loss of $6.4 million, while highlighting significant business progress. The company completed dosing in its SLIM-1 Phase 1 trial of NPM-139, a novel semaglutide implant for chronic weight management, with top-line data expected in November 2026. Vivani entered a non-exclusive agreem…